| ²é¿´: 763 | »Ø¸´: 6 | |||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷ÕߺìòßòѺÃÔ˽«ÔùËÍÄú 20 ¸ö½ð±Ò | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
ºìòßòѺÃÔËÒø³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
IRB approval or waiver statement in the Materials and Methods section. ÒÑÓÐ2È˲ÎÓë
|
||
|
Include IRB approval or waiver statement in the Materials and Methods section. The Clinical Trial Registration number, if applicable, should be included at the end of the abstract. sciͶ¸å£¬ÈÃУ¸å¡£±à¼·¢ÁËÕâ¸ö£¬Ê²Ã´Òâ˼£¿ÊÇÐèÒª¼Óʲô˵Ã÷Âð£¿Âé·³³æÓÑÖ¸µã£¬¶àл¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
» ²ÂÄãϲ»¶
308Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ6È˻ظ´
332²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
334Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
324Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
2026Ä격ʿÃû¶î¼ñ©
ÒѾÓÐ5È˻ظ´
274Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
AÇøÒ»±¾½»²æ¿ÎÌâ×飬µÍ·Öµ÷¼Á£¬ÕÐÊÕ»úеµç×ÓÐÅϢͨÐŵȽ»²æ·½Ïò
ÒѾÓÐ29È˻ظ´
328Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²»ÏÞѧУרҵµÄµ÷¼Áͬѧ¿´¹ýÀ´
ÒѾÓÐ8È˻ظ´
ÆÚ¿¯¹àË®¸ßÊÖ
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 386.3
- ɳ·¢: 2
- Ìû×Ó: 97
- ÔÚÏß: 5.1Сʱ
- ³æºÅ: 34427710
- ×¢²á: 2024-01-14
- רҵ: ¿µ¸´Ò½Ñ§
|
ÁÙ´²ÊÔÑéÐèÒªÂ×ÀíÎÄÔ±»áµÄÅú×¼Îļþ£¬ÄãÐèÒªÔÚmethod²¿·ÖÌṩÂÛÎĵÄÊÔÑé»ñµÃËùÔÚ»ú¹¹Â×ÀíίԱ»áµÄÉùÃ÷£¬¿ÉÒԵϰÔÚժҪĩβ¸½ÉÏÁÙ´²ÊÔÑéµÄ×¢²á±àºÅ ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
3Â¥2024-02-10 12:27:47
ºìòßòѺÃÔË
Òø³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 10589.6
- É¢½ð: 220
- ºì»¨: 3
- Ìû×Ó: 1678
- ÔÚÏß: 179.8Сʱ
- ³æºÅ: 1475612
- ×¢²á: 2011-11-04
- ÐÔ±ð: MM
- רҵ: »·¾³»¯Ñ§
2Â¥2024-02-10 11:10:03
ÆÚ¿¯¹àË®¸ßÊÖ
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 386.3
- ɳ·¢: 2
- Ìû×Ó: 97
- ÔÚÏß: 5.1Сʱ
- ³æºÅ: 34427710
- ×¢²á: 2024-01-14
- רҵ: ¿µ¸´Ò½Ñ§
|
*»ñµÃËùÔÚ»ú¹¹Â×ÀíίԱ»áÅú×¼µÄÉùÃ÷ ˳±ãסÌâÖ÷дº¿ìÀÖ£¬ÍòÊÂÈçÒâ ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
4Â¥2024-02-10 12:29:58
ºìòßòѺÃÔË
Òø³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 10589.6
- É¢½ð: 220
- ºì»¨: 3
- Ìû×Ó: 1678
- ÔÚÏß: 179.8Сʱ
- ³æºÅ: 1475612
- ×¢²á: 2011-11-04
- ÐÔ±ð: MM
- רҵ: »·¾³»¯Ñ§
5Â¥2024-02-10 12:35:02













»Ø¸´´ËÂ¥
ºìòßòѺÃÔË
6